ArticleBioinformation2025
MALAT1 and HIST1H2BC as connecting diagnostic biomarkers in Ebola and its overlapping disease: An integrative approach.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diagnostic biomarker for Ebola Virus Disease (EVD) and its overlapping diseases, which include COVID-19, monkey pox, AIDS and uveitis, is of interest. The gene-disease association network was built by using human microarray datasets from the GEO database. The comparison based on Jaccard's similarity index showed 27 intersected differentially expressed genes (DEGs), with AIDS having the highest genomic association with EVD. Gene-disease interaction analysis revealed Metastasis-associated lung adenocarcinoma transcript-1 (MALAT1) and histone cluster 1, H2bc (HIST1H2BC) as the most relevant diagnostic biomarkers. Thus, the dg IDB database provided potential for drug repurposing, targeted therapy and broad-spectrum antiviral applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.